Foamix starts efficacy trial of rosacea treatment

The company plans to continue development of the product independently.

Foamix Ltd. has begun a Phase II clinical trial (efficacy and safety) of its Topical Minocycline Foam for patients suffering from Rosacea, a chronic condition characterized by facial erythema (redness), and sometimes known as adult acne.

Currently, Minocycline is only offered in oral form, and there is no product on the market for delivering the drug through the skin.

Foamix said that in laboratory studies, it effectively killed various bacteria that cause acne, and that transdermal delivery of the product was sufficient to treat the disease, without penetrating too deep to reach the bloodstream. The clinical trial is being conducted according to US Food and Drug Administration (FDA) protocols, but it is not being conducted vis-à-vis the FDA.

Foamix's product can also treat regular acne, skin inflammations, and chronic wounds, as well as rosacea. The company plans to continue development of the product independently, in contrast to other products which it is developing jointly with other drug companies.

"We are preparing to invest what is needed to bring the product to market independently," said Foamix CEO Dr. Dov Tamarkin. "We're not trying at the moment to sell the rights to it to another company. If we get the right offer, we'll be very happy."

Published by Globes [online], Israel business news - - on January 20, 2011

© Copyright of Globes Publisher Itonut (1983) Ltd. 2011

Twitter Facebook Linkedin RSS Newsletters גלובס Israel Business Conference 2018